Valuation : Avacta Group Plc

Market Cap 324M 440M 378M 354M 611M 42.07B 612M 4.19B 1.64B 21.2B 1.65B 1.62B 70.17B P/E 2026 *
-9.9x
P/E 2027 * -10.2x
Enterprise Value 319M 433M 372M 348M 600M 41.34B 602M 4.12B 1.61B 20.84B 1.63B 1.59B 68.96B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Avacta Group Plc

1 day+0.78%
1 week+3.94%
Current month+3.21%
1 month+3.21%
3 months-6.45%
6 months+7.53%
Current year+20.25%
1 week 0.93
Extreme 0.9283
0.94
1 month 0.9
Extreme 0.9
0.94
Current year 0.74
Extreme 0.7384
1.23
1 year 0.74
Extreme 0.7384
1.23
3 years 0.4
Extreme 0.4011
2.17
5 years 0.4
Extreme 0.4011
2.29
10 years 0
Extreme 0
3.5
Manager TitleAgeSince
Chief Executive Officer 56 31/03/2024
Director of Finance/CFO 51 21/01/2025
Chief Tech/Sci/R&D Officer - 08/02/2026
Director TitleAgeSince
Director/Board Member 60 02/02/2020
Director/Board Member 71 16/08/2021
Director/Board Member 56 17/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+3.94% - - 441M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.23% 65.4B
-0.48%+0.90%+8.62%-7.28% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-1.59%-2.18%-9.05%+465.91% 27.16B
+0.37%+1.21%+36.55%-17.60% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.72%+2.68%+43.16%+148.56% 13.9B
Average +0.31%+1.16%+57.99%+193.44% 32.03B
Weighted average by Cap. +0.87%+0.72%+55.48%+155.56%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -45.39M -38.97M -36.48M -62.93M -4.34B -63.11M -432M -169M -2.19B -170M -167M -7.23B -32.74M -44.48M -38.19M -35.75M -61.67M -4.25B -61.84M -423M -165M -2.14B -167M -163M -7.09B
Net Debt -5.58M -7.58M -6.51M -6.09M -10.51M -724M -10.54M -72.13M -28.2M -365M -28.46M -27.84M -1.21B 21.72M 29.51M 25.33M 23.72M 40.91M 2.82B 41.03M 281M 110M 1.42B 111M 108M 4.7B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
25/08/26 US$0.9355 +0.78% 5,000
21/08/26 US$0.9283 +3.14% 100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6920GBP
Average target price
0.8167GBP
Spread / Average Target
+18.02%

Annual profits - Rate of surprise